Modality
Bispecific Ab
MOA
HER2
Target
PD-L1
Pathway
Neuroinflam
PsA
Development Pipeline
Preclinical
~Oct 2010
→ ~Jan 2012
Phase 1
~Apr 2012
→ ~Jul 2013
Phase 2
~Oct 2013
→ ~Jan 2015
Phase 3
~Apr 2015
→ ~Jul 2016
NDA/BLA
~Oct 2016
→ ~Jan 2018
Approved
Apr 2018
→ Sep 2031
ApprovedCurrent
NCT03787842
355 pts·PsA
2018-04→2029-06·Active
NCT06001305
867 pts·PsA
2023-08→2026-08·Recruiting
NCT08078776
496 pts·PsA
2021-08→2031-08·Terminated
+1 more trial
4,427 total pts1 indication
CompletedCurrentUpcoming
Catalysts (4)
2026-08-215mo awayPh3 Readout· PsA
2029-06-153.2y awayPh3 Readout· PsA
2031-08-165.4y awayPh3 Readout· PsA
2031-09-105.4y awayPh3 Readout· PsA
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Active
Approved
Termina…
Approved
Active
Approved
Recruit…
Catalysts
Ph3 Readout
2026-08-21 · 5mo away
PsA
Ph3 Readout
2029-06-15 · 3.2y away
PsA
Ph3 Readout
2031-08-16 · 5.4y away
PsA
Ph3 Readout
2031-09-10 · 5.4y away
PsA
RecruitingActiveTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03787842 | Approved | PsA | Active | 355 | HAM-D |
| NCT06001305 | Approved | PsA | Recruiting | 867 | VA |
| NCT08078776 | Approved | PsA | Terminated | 496 | BodyWt |
| NCT04249295 | Approved | PsA | Active | 2709 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 |